Cargando…
Vascular endothelial growth factor inhibitors for predominantly Caucasian myopic choroidal neovascularization: 2‐year treatment outcomes in clinical practice: data from the Fight Retinal Blindness! Registry
PURPOSE: To report the 24‐month outcomes of vascular endothelial growth factor (VEGF) inhibitors for myopic choroidal neovascularization (mCNV) in predominantly Caucasian eyes in routine clinical practice. METHODS: Retrospective analysis of treatment‐naïve eyes starting intravitreal injection of VEG...
Autores principales: | Gabrielle, Pierre‐Henry, Nguyen, Vuong, Creuzot‐Garcher, Catherine, Miguel, Lucia, Alforja, Socorro, Sararols, Laura, Casaroli‐Marano, Ricardo P., Zarranz‐Ventura, Javier, Gillies, Mark, Arnold, Jennifer, Barthelmes, Daniel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290852/ https://www.ncbi.nlm.nih.gov/pubmed/33960115 http://dx.doi.org/10.1111/aos.14893 |
Ejemplares similares
-
Dexamethasone Implant for Diabetic Macular Oedema: 1-Year Treatment Outcomes from the Fight Retinal Blindness! Registry
por: Bhandari, Sanjeeb, et al.
Publicado: (2022) -
Multimodal imaging and diagnosis of myopic choroidal neovascularization in Caucasians
por: Milani, Paolo, et al.
Publicado: (2016) -
Neovascular age‐related macular degeneration: A review of findings from the real‐world Fight Retinal Blindness! registry
por: Nguyen, Vuong, et al.
Publicado: (2021) -
Initial observation or treatment for diabetic macular oedema with good visual acuity: two‐year outcomes comparison in routine clinical practice: data from the Fight Retinal Blindness! Registry
por: Gabrielle, Pierre‐Henry, et al.
Publicado: (2020) -
THREE-YEAR TREATMENT OUTCOMES OF AFLIBERCEPT VERSUS RANIBIZUMAB FOR DIABETIC MACULAR EDEMA: Data from the Fight Retinal Blindness! Registry
por: Gabrielle, Pierre-Henry, et al.
Publicado: (2022)